Published in Healthcare Mergers, Acquisitions and Ventures Week, February 16th, 2008
"The '103 Anemia of Cancer' study, a Phase 3 trial designed to test whether anemic patients with active cancer not receiving concurrent chemotherapy or radiotherapy benefit from treatment with Aranesp, was previously reported by Amgen when results became available in 2007. The results of this study were provided to regulatory agencies, communicated to physicians through a 'Dear Healthcare...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week